Drug news
NICE recommends use of Tarceva for relapsed NSCLC - Roche
NICE has changed its previous recommendation, and now supports the continued use of Tarceva (erlotinib), from Roche, as a second-line treatment for patients with Non-Small Cell Lung Cancer. In February, NICE issued an announcment that it would be limiting access to Tarceva after a review found that the drug no longer met NICE criteria for clinical and cost-effectiveness. Following consultation, NICE has modified the draft guidance to allow the continued use of the drug for relapsed NSCLC.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.